Harpreet S. Bajaj MD, MPH, FACE
Endocrinologist and Medical Director, Endocrine & Metabolic Research, LMC Healthcare; Research Associate, Mount Sinai Hospital, Toronto; Adjunct Lecturer, McMaster University Toronto, Ontario, CanadaHarpreet Singh Bajaj is an Endocrinologist and Medical Director of Endocrine & Metabolic Research at LMC Healthcare/Centricity Research in Canada. Dr Bajaj completed his endocrinology fellowship at the Cleveland Clinic (Ohio, USA). Dr. Bajaj’s medical education was at University of Delhi, India, followed by a Masters of Public Health (Epidemiology) at State University of New York in Albany (New York, USA).
Dr. Bajaj’s research focus and publications in key medical journals relate to type 2 diabetes (prevention, remission and management), obesity and cardiorenal risk reduction.
He is the Principal Investigator of the Canadian Diabetes Prevention Program, a nationwide collaborative effort between LMC, Diabetes Canada funded by the Public health agency of Canada. Dr. Bajaj currently serves Diabetes Canada as the Chair of the Clinical Practice Guidelines Steering Committee.
Disclosures
Dr. Bajaj is a principal investigator for BIF and icodec insulin research trials.He also reports the following:
Research Studies/Grants: Amgen, Anji, AstraZeneca, Boehringer Ingelheim, Canadian Institutes of Health Research (CIHR), Eli Lilly, Kowa, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Public Health Agency of Canada (PHAC), Sanofi Speaking Honoraria: American Diabetes Association (ADA), Canadian Diabetes & Endocrinology Today, Canadian Hypertension Education Program (CHEP+), Canadian Society of Endocrinology & Metabolism (CSEM), Emirates Diabetes & Endocrine Society (EDES), Endocrine Society, International Diabetes Federation (IDF), LMC Physicians Inc., Medscape, Center for Advanced Clinical Solutions, Windsor Heart Institute Advisory or consultancy fee/Stocks: none.